Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-04 · 18 (2)
DOI: 10.1002/dad2.70348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 28.05.2026. Verfasst von Yuxin Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology Shandong Provincial Hospital Shandong First Medical University Jinan China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shandong Province, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Lecanemab provides clinical benefits in early Alzheimer's disease (AD), but its longitudinal effects on brain structure, particularly cerebrospinal fluid (CSF) compartments, remain unclear. This study examined treatment‐associated structural changes using longitudinal MRI. METHODS Thirty‐one patients with mild cognitive impairment (MCI) or early AD underwent baseline and follow‐up (1–7 months) 3D T1‐weighted MRI during lecanemab treatment. Gray matter (GM), ventricular, choroid plexus (CP), and perivascular space (PVS) volumes were quantified. Longitudinal changes were analyzed with paired tests and linear mixed‐effects models (LMMs). RESULTS Significant GM volume reductions were observed in AD‐vulnerable regions (hippocampus, entorhinal cortex, precuneus), with increased CSF volumes. PVS volume showed a modest, non‐significant decline. CP enlargement was associated with ventricular expansion. DISCUSSION Lecanemab treatment was associated with coordinated parenchymal and CSF‐related structural changes. CP and PVS dynamics may represent potential MRI‐based markers for monitoring early AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology Shandong Provincial Hospital Shandong First Medical University Jinan China.
- Department of Neurology Shandong Provincial Hospital Shandong First Medical University Jinan China.
- MR Research Collaboration Team Siemens Healthineers Ltd. Shanghai China.
Förderung
- Natural Science Foundation of Shandong Province
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Li, Y., Zhao, Y., Yang, A., Wang, Y., Xin, J., Chen, Y., Xing, X., Liu, F., Zou, Y., Zhao, W., Song, L., Gong, T., & Wang, G. (2026). Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 18(2). https://doi.org/10.1002/dad2.70348
Vancouver
Li Y, Zhao Y, Yang A, Wang Y, Xin J, Chen Y, et al. Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2026;18(2). doi:10.1002/dad2.70348
BibTeX
@article{Li2026,
author = {Li, Yuxin and Zhao, Yang and Yang, Aocai and Wang, Yan and Xin, Jiaxiang and Chen, Yufan and Xing, Xuewen and Liu, Fei and Zou, Yao and Zhao, Wei and Song, Lin and Gong, Tao and Wang, Guangbin},
title = {Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2026},
volume = {18},
number = {2},
doi = {10.1002/dad2.70348}
}
EUVIMED